Targeting the Nine Hallmarks of Aging on DNA Methylation

TruDiagnostic

Status and phase

Enrolling

Phase 2

Conditions

Aging

Treatments

Dietary Supplement: SRW Cel System

Study type

Interventional

Funder types

Industry

Other

Identifiers

NCT05535608

10349 (Other Identifier)

Details and patient eligibility

About

SRW Laboratories has formulated the Cel System protocol, a group of three formulas designed to interact with each of the 9 Hallmarks of Aging and combined this with an App that supports positive lifestyle changes, with a view that, if we can positively impact each Hallmark, we can support healthy aging.

Full description

This study will measure the impact of the Cel System protocol on the biological clocks of the participants, as well as measure established biomarkers associated with the 9 Hallmarks and note any aesthetic changes you may experience to establish evidence of the effect of the Cel System Protocol over time.

Enrollment

50 estimated patients

Sex

All

Ages

55 to 90 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Men and women of any ethnicity
55 years and older
Female subjects must be post-menopausal
Participant must be able to comply with treatment plan and laboratory tests
Participant must be able to read, write, and speak English fluently
Participant must have a smartphone and be able to download and use the App
Participant must have an established primary care provider
Participant must be willing and able to consume study supplements throughout the duration of study period

Exclusion criteria

History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer.
Known immune system issues or immunodeficiency disease
History of viral illness which could be reactivated by immune downregulation
Presence of clinically significant acute or unstable cardiovascular and cerebrovascular (stroke) disease
Diagnosis of a transient ischemic attack in the 6 months prior to screening
Participants infected with hepatitis C or HIV
Presence of active infection in previous 4 weeks
Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the Clinical Investigator would render a participant unsuitable to participate in the study
Unable or unwilling to provide required blood sample for testing
Current or previous use of known prescription immunomodulating products (e.g. glucocorticoids, TNF-alpha inhibitors) in the month prior to the start of the trial.
A known history of blood dyscrasias including coagulopathy
Any person deemed by the Investigator as having a low likelihood of complying with study protocol (e.g. evidence of history of non-compliance, history of poor follow-up, multiple or complex scheduling conflicts).
Planned surgical procedure during study period
Participants who are actively engaged in a weight loss program or have started any new medications during the duration of the trial that can potentially interfere with the study, as deemed appropriate by Principal Investigator.